Tiny Sponges to Fight Severe Drug-Resistant Lung Infections
Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN DIEGO · NIH-11123206
This project is developing tiny, cell-like particles to help the body fight severe, drug-resistant lung infections common in hospitals.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN DIEGO (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-11123206 on ClinicalTrials.gov |
What this research studies
Pneumonia, especially in hospitals, can be very serious, particularly when bacteria become resistant to common medicines. These infections can also cause too much inflammation, damaging the lungs. Our approach involves creating special nanoparticles, which are like tiny sponges, coated with membranes from human immune cells called macrophages. These "nanosponges" are designed to act in two ways: first, they can soak up harmful bacterial toxins and, second, they can help calm down the excessive inflammation that often makes lung infections worse. This dual action aims to help the body clear the infection and protect the lungs from damage.
Who could benefit from this research
Good fit: This research is focused on critically ill patients with severe lung infections, specifically hospital-acquired pneumonia caused by multidrug-resistant Pseudomonas aeruginosa or Acinetobacter baumannii.
Not a fit: Patients with less severe forms of pneumonia, or those caused by different types of bacteria that respond to standard antibiotics, may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this new treatment could significantly improve outcomes for critically ill patients suffering from severe, drug-resistant hospital-acquired pneumonia by both fighting infection and reducing harmful inflammation.
How similar studies have performed: This project describes a highly innovative drug concept with a unique, multifold mechanism of action, suggesting it is a novel approach to treating these challenging infections.
Where this research is happening
LA JOLLA, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN DIEGO — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NIZET, VICTOR — UNIVERSITY OF CALIFORNIA, SAN DIEGO
- Study coordinator: NIZET, VICTOR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.